Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours

European Journal of Cancer Part A

Volumn 33, Issue 6, 1997, Pages 843-847

  Hartmann, J T ^a   Candelaria, M ^a   Kuczyk, M A ^b   Schmoll, H J ^c   Bokemeyer, C ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Multiple surgical interventions; Non seminomatous germ cell tumour; Residual tumour masses; Testicular cancer

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE;

ADOLESCENT; ADULT; ARTICLE; CANCER LOCALIZATION; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NON SEMINOMATOUS GERMINOMA; OUTCOMES RESEARCH; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; SURGICAL MORTALITY; TESTIS CANCER; TUMOR NECROSIS;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; GERMINOMA; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; NECROSIS; RETROPERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; TESTICULAR NEOPLASMS;

EID: 0030790346     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00517-5     Document Type: Article

References (31)

1. Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990, 8, 1777-81.
2. Donohue JP, Rowland RG. The role of surgery in advanced testicular cancer. Cancer 1984, 54, 2716-2721.
3. Tait D, Peckham MJ, Hendry WR, Goldstraw P. Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: the significance of histology with particular reference to differentiated (mature) teratoma. Br J Cancer 1984, 50, 601-609.
4. Tiffany P, Morse MJ, Bosl G, et al. Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumours. Cancer 1986, 57, 978-983.
5. Harding MJ, Brown IL, MacPherson SG, Turner MA, Kaye SB. Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours. Eur J Cancer Clin Oncol 1989, 25, 1689-1694.
6. Toner GC, Panicek DM, Heelan RT, et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumours: recommendations for patient selection. J Clin Oncol 1990, 8, 1683-1694.
7. Qvist HL, Fosså SD, Ous S, Hoie J, Stenwig AE, Giercksky KE. Post-chemotherapy tumour residuals in patients with advanced nonseminomatous testicular cancer. Is it necessary to resect all residual masses? J Urol 1991, 145, 300-303.
8. Kulkarni RP, Reynolds KW, Newlands ES, et al. Cytoreductive surgery in disseminated non-seminomatous germ cell tumours of testis. Br J Surg 1991, 78, 226-229.
9. Brenner PC, Harry W, Morse MJ, Sheinfeld J, et al. Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumours of the testis. J Clin Oncol 1996, 14, 1765-1769.
10. Aprikian AG, Herr HW, Bajorin DF, Bosl GJ. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumours. Cancer 1994, 74, 1329-1334.
11. Donohue JP, Fox EP, Williams SD, et al. Persistent cancer in postchemotherapy retroperitoneal lymph-node dissection: outcome analysis. World J Urol 1994, 12, 190-195.
12. Fox EP, Weathers TD, Williams SD, et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumour in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol 1993, 11, 1294-1299.
13. Gerl A, Clemm C, Schmeller N, Dienemann H, et al. Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours. Br J Cancer 1994, 70, 960-965.
14. Madnelbaum I, Yaw PB, Einhorn LH, Williams SD, Rowland RG, Donohue JP. The importance of one-stage median sternotomy and retroperitoneal node dissection in disseminated testicular cancer. Ann Thorac Surg 1983, 36, 524-528.
15. Birch R, Williams S, Cone A, Einhorn L, et al. Prognostic factors for favourable outcome in disseminated germ cell tumours. J Clin Oncol 1986, 4, 400-407.
16. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumours with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987, 316, 1435-1440.
17. Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977, 87, 293-298.
18. Harstrick A, Schmoll HJ, Kohne-Wompner CH, Bergmann L, et al. Cisplatin, etoposide, ifosfamide, vincristine and bleomycin combination chemotherapy for far advanced testicular carcinoma. Ann Oncol 1991, 2, 197-202.
19. Loehrer PJ Sr, Lauer R, Roth BJ, Williams SD, Kalasinski LA, Einhorn LH. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 1988, 109, 540-546.
20. Pugh RCB. Testicular tumours. In Pugh RCB, ed. Pathology of the Testis. Oxford, Blackwell Scientific Publications, 1976, 139-162.
21. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958, 53, 457-481.
22. Levi JA, Thomson D, Sandeman T, et al. A prospective study of cisplatin-based combination chemotherapy in advanced germ cell malignancy: role of maintenance and long-term follow-up. J Clin Oncol 1988, 6, 1154-1160.
23. Peckham MJ, Horwich A, Easton DF, Hendry WF. The management of advanced testicular teratoma. Br J Urol 1988, 62, 63-68.
24. Stoter G, Koopman A, Vendrik CP, et al. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol 1989, 7, 1099-1104.
25. Levitt MD, Reynolds PM, Sheiner JH, Byrne MJ, et al. Non-seminomatous germ cell testicular tumours: residual masses after chemotherapy. Br J Surg 1985, 72, 19-22.
26. Fossa SD, Qvist H, Stenwig AE, Lien HH, Ous S, Giercksky KE. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumour masses? J Clin Oncol 1992, 10, 569-573.
27. Donohue JP, Rowland RG, Kopecky K, et al. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol 1987, 137, 1176-1179.
28. Gelderman WA, Schraffordt-Koops H, Sleijfer DT, et al. Results of adjuvant surgery in patients with stage III and IV nonseminomatous testicular tumours after cisplatin-vinblastine-bleomycin chemotherapy. J Surg Oncol 1988, 38, 227-232.
29. Roth BJ, Greist A, Kubilis PS, Williams SD, Einhorn LH. Cisplatin-based combination chemotherapy for disseminated germ cell tumours: long-term follow-up. J Clin Oncol 1988, 6, 1239-1247.
30. Stephens WS, Gonin R, Hutchins GD, Einhorn LH. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumour patients. J Clin Oncol 1996, 14, 1637-1641.
31. Steyerberg EW, Keizer HJ, Fossa SD, et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 1995, 13, 1177-1187.